BPCR — Biopharma Credit Balance Sheet
0.000.00%
Last trade - 00:00- $1.06bn
- $1.05bn
- $157.78m
Annual balance sheet for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 94.7 | 121 | 86.2 | 5.62 | 12.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10 | 19.8 | 20.3 | 31.8 | 53.6 |
| Total Other Current Assets | |||||
| Total Current Assets | 105 | 140 | 155 | 37.4 | 66.2 |
| Long Term Investments | |||||
| Total Assets | 1,371 | 1,364 | 1,357 | 1,200 | 1,168 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.34 | 26.3 | 15.9 | 17.9 | 17.6 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.9 | 26.6 | 15.9 | 17.9 | 17.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 1,364 | 1,337 | 1,341 | 1,182 | 1,151 |
| Total Liabilities & Shareholders' Equity | 1,371 | 1,364 | 1,357 | 1,200 | 1,168 |
| Total Common Shares Outstanding |